SCHEMBL636933

SCHEMBL636933

CC(=O)CC(C)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13225448 1.00
SCHEMBL25168749 1.00
Hydrochloric Acid SCHEMBL15994261 0.97
Hydrochloric Acid SCHEMBL30505671 0.97
SCHEMBL12238522 0.80
SCHEMBL16388297 0.79
SCHEMBL14288629 0.79
SCHEMBL13397307 0.79
SCHEMBL21790235 0.78 ALDH1A1 (0.48)
SCHEMBL17810229 0.78 ALDH1A1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421249-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-09-23 US disclosed
US-20240368180-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2024-11-07 US disclosed
EP-4440697-A1 SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USING SAME Vertex Pharmaceuticals Incorporated (US) 2024-10-09 EP disclosed
WO-2024052333-A1 MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS PHILOCHEM AG (CH) 2024-03-14 WO disclosed
US-11866446-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-01-09 US disclosed
US-20230340199-A1 POLYAMIDES, AND METHODS OF PRODUCING THEREOF NOVOMER, INC. 2023-10-26 US disclosed
US-11718714-B2 Polyamides, and methods of producing thereof NOVOMER, INC. (US) 2023-08-08 US disclosed
CN-116547287-A Inhibitors of APOL1 and methods of use thereof 弗特克斯药品有限公司 2023-08-04 CN disclosed
EP-4204423-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME Vertex Pharmaceuticals Incorporated (US) 2023-07-05 EP disclosed
US-20230203000-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-06-29 US disclosed
US-20210189211-A1 THERMALLY-CONDUCTIVE GAP FILLER 3M INNOVATIVE PROPERTIES COMPANY 2021-06-24 US disclosed
US-20210163505-A1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-06-03 US disclosed
WO-2018132189-A1 GLYCERYL 3-HYDROXYBUTYRATES FOR TRAUMATIC BRAIN INJURY NEUROENERGY VENTURES, INC. (US) 2018-07-19 WO disclosed
US-20160297823-A1 SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME INSTITUTE FOR DRUG DISCOVERY, LLC 2016-10-13 US disclosed
US-9244034-B2 Electrochemical pH measurement SCHLUMBERGER TECHNOLOGY CORPORATION (US) 2016-01-26 US disclosed
WO-2015095701-A1 SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME THE INSTITUTE FOR DRUG DELIVERY (US) 2015-06-25 WO disclosed
US-8119364-B2 Methods for generating analogs of coenzyme A THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-21 US disclosed
US-20100304430-A1 Methods for Generating Analogs of Coenzyme A THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-12-02 US disclosed
US-7727738-B2 Methods for generating analogs of coenzyme A THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-06-01 US disclosed
US-20070128683-A1 Metabolic delivery of coenzyme A analogs NATIONAL SCIENCE FOUNDATION 2007-06-07 US disclosed